- Charles River Laboratories and MEDIPOST have signed a non-exclusive memorandum of understanding to collaborate on GMP-compliant testing and commercial support for cell therapy programs.
- The partnership will initially focus on the Asia-Pacific and North America regions, with potential expansion into Europe and the Middle East.
Charles River Laboratories and MEDIPOST Co., Ltd. have entered into a non-exclusive memorandum of understanding to collaborate on GMP-compliant testing services and broader commercial and marketing activities supporting cell therapy development and commercialization.
According to the companies, the collaboration will combine Charles River’s biologics and cell therapy GMP testing capabilities with MEDIPOST’s cell therapy development and manufacturing programs. The partnership will initially support activities in the Asia-Pacific and North America regions, with potential future expansion into Europe and the Middle East.
Charles River stated that it will provide biologics quality control, viral testing, release testing, and other GMP-compliant services to support MEDIPOST from development through commercialization. The companies said the agreement is intended to support compliant development pathways for advanced biologics and cell therapy products across multiple regulatory markets.
“We are excited to deepen our partnership with MEDIPOST and collaborate with a top global cell therapy developer, assisting at both clinical and commercialization phases.”
Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River
MEDIPOST stated that it has more than 14 years of commercial-stage allogeneic cell therapy manufacturing and release experience and has treated more than 36,000 patients in South Korea. The company added that the collaboration with Charles River will support its plans to expand cell therapy commercialization activities globally through compliant manufacturing and testing pathways.
